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Abstract 
BACKGROUND: The prevalence of cardiovascular disease (CVD) and its mortality continues to increase. Various 
studies have shown aspirin can reduce CVD mortality but has adverse side effects. Research on a comparison 
between aspirin and honey has not been done, but both have antiplatelet effects.  
AIM: This study is aimed to prove the antiplatelet effects on honey and compare the antiplatelet effects of aspirin 
with honey based on the bleeding time in mice.  
METHODS: This study is a true experimental design with a post-test only control group using 32 male mice, 
Double Ditsch Webster, ± 3 months old, the weight of 20-30 g, divided into 4 groups. Consisting of a negative 
control group (placebo), aspirin and honey. The suspension has given orally for 12 days using the probe. The 
research was conducted at the Laboratory of Pharmacology Department of Pharmacology and Therapeutics 
Faculty of Medicine, the University of North Sumatra in September until December 2015. The data collected was 
bleeding time in mice. Data analysed by Shapiro Wilk test, Kruskal Wallis and Mann Whitney.  
RESULTS: The mean bleeding time was a placebo (102.88 seconds), aspirin (369.38 seconds) and honey 
(304.63 seconds). Mann Whitney test showed significant results in the aspirin and honey groups against the 
control group (placebo) with p = 0.001. There were no significant differences in the aspirin group against honey (p 
= 0.172). Honey has an antiplatelet effect in mice. The mean bleeding time in mice given honey is longer or closer 
to the mean bleeding time in the aspirin group.  
CONCLUSION: The results could be used as a basis for further research to determine its use in humans with 
cardiovascular disease. 
 
 
 
Introduction 
 
Hemostasis is a body reaction that occurs 
sequentially to stop the bleeding. When blood vessels 
are damaged or broken, then the hemostasis process 
must occur quickly in areas that have been damaged 
and carefully controlled to be effective. Three major 
mechanisms that occur to reduce blood loss are 
vascular spasm, platelet plug formation, and 
coagulation (blood clotting) [1]. 
The process of hemostasis can occur without 
any additional injury to the blood vessels of patients 
with a history of heart disease and abnormalities in 
blood vessels [1]. In other words, thrombosis is the 
formation of a pathological hemostatic plugin blood 
vessels that do not bleed [2]. For example, in patients 
with transient ischemic attacks (TIAs), 
cerebrovascular disease (stroke), myocardial 
infarction or peripheral artery blockage are classified 
as cardiovascular disease (CVD) [3]. 
Cardiovascular disease (CVD) is the leading 
cause of disability and premature death worldwide. 
The underlying pathology of CVD is atherosclerosis 
[4]. According to the World Health Organization 
(WHO) in 2012 [5]. Deaths caused by 
noncommunicable diseases (NCDs) account for 38 
million of the 56 million global deaths, which is about 
68%. The main cause of NCD death in 2012 is 
cardiovascular disease (CVD) that is as many as 17.5 
million deaths, or 46% of all deaths due to NCD. 
In the Asia / Pacific region, the main cause of 
death is CVD, which is estimated at 9.3 million deaths 
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and accounts for about a third of all deaths in 2012 
[3]. 
According to WHO-Noncommunicable 
Diseases (NCD), Country Profiles in 2014 [6]. 
Cardiovascular disease (CVD) has been the leading 
cause of death in Indonesia, which is about 37% of all 
deaths (1,551,000) in the country. 
Administration of antiplatelet drugs such as 
aspirin can reduce mortality caused by CVD. This 
antiplatelet therapy is said to be effective in treating 
severe vascular disease with both short-term and 
long-term administration [7]. Aspirin (Acetylsalicylic 
acid-ASA) works by inhibiting the synthesis of 
thromboxane A2 (TXA2) in platelets and prostacyclin 
(PGI2) in blood vessels by irreversibly inhibiting cyclo-
oxygenase enzymes [8]. However, the dose of aspirin 
used as an antiplatelet drug in clinical trials is not 
equivalent [9]. Excessive administration of single-dose 
aspirin, as well as long-term, can cause the risk of 
poisoning [10]. The severity of complications that 
occur with aspirin depends on the dose and duration 
of treatment. Complications can include bleeding and 
perforation of the gastrointestinal system [11]. It turns 
out that any pharmacological therapy has adverse 
side effects either directly or indirectly. Then safe, 
natural ingredients are needed as alternative 
pharmacological therapies or as supplements [12]. 
Honey is a sweet and thick liquid with a 
unique flavour generated by honeybees [13]. Honey is 
very efficacious in medical therapy because of the 
existence of various phenolic components that have 
many biological activities, including antioxidants and 
anti-inflammatory [14]. Research conducted by 
Ahmed et al., in 2011 [15], proved to have the effect of 
anti-platelet honey. Honey contains flavonoids, 
including hesperetin that serves as anti platelet 
aggregation [16]. 
With the effect of antiplatelet on honey, the 
researchers are interested in researching the 
comparison of the effectiveness of aspirin with honey 
as antiplatelet based on measurement of bleeding 
time on the tail of mice. This research is expected to 
be useful in preventing CVD both in primary and 
secondary. 
 
 
Material and Methods 
 
Types of Research 
This research is a true experimental design 
because it performs randomisation (simple random 
sampling), control, and treatment. The study design is 
the posttest-only control group design.  
P = Population (Mice); 
R = Randomization; 
K1 = Ex. Plasebo Control (-) without 
treatment; 
K2 = Ex. Plasebo Control (+) with aspirin 
administration without treatment; 
K3 = Ex. Treatment by giving oral Honey for 
12 days. 
 
Simple random sampling 
1. Number labels are created on each animal 
that meets the inclusion criteria. 
2. Then select as many as 32 mice from them 
to be sampled and divided into 4 groups at random. 
Provision of intervention in experimental 
animals (mice) was made single-blind. 
 
Time and Place of Study 
This research has been conducted in 
Pharmacology Laboratory of Department of 
Pharmacology and Therapeutics Faculty of Medicine, 
University of Sumatera Utara. This research has been 
conducted from September to December 2015. 
Research has been conducted after obtaining 
approval from Ethical Clearance from the Ethics 
Commission of the Faculty of Medicine, University of 
North Sumatra. 
 
Population and Sample Research 
In this study have been used male mice (Mus 
musculus), Double Ditsch Webster strains age: ± 3 
months (adult), weight 20-30 grams, healthy, has 
never been used for other studies. Mice obtained from 
Laboratorium FMIPA Biology University of North 
Sumatra Medan. The number of group animals is 
determined by the formula, according to Federer 
(1963), as follows: 
(t-1) (n-1) ≥ 15 
Explanation: 
n = sample size 
t = number of groups of experimental animals 
Then the required sample size is: 
(t-1) (n-1) ≥ 15 
(4-1) (n-1) ≥ 15 
(n-1) ≥ 5 
n ≥ 6 
It takes a sample of six animals for each 
group based on Federer's formula. Added with an 
estimated drop out of 10%, then the minimum sample 
size required for each group are seven animals. 
Based on the minimum number of samples 
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allowed statistically and not violating the 3 R 
(Reduction, Replacement, Refinement) principles in 
the experimental animal studies, the sample size is 
taken to eight for each group. So, the total number of 
experimental animals used is 32 mice. 
 
Criteria for Inclusion, Exclusion and Drop 
 Out 
Inclusion Criteria: 1. Mice (Mus musculus) 
strain Double Ditsch Webster, male, age: 2-3 months, 
weight: 20-30 grams and 2. Mice healthy, active 
moves and come from the same group 
Exclusion Criteria: Previous mice have 
received drug intervention. 
Drop Out Criteria: Mice die within the study 
period. 
 
Material 
In this study, the materials used are 1. High 
Desert® 75 mg Honey and 2. Aspirin 80 mg. 
 
Preparing and Maintaining Animals Try 
Before the study, the adaptation of animals at 
the site with a light 12-hour cycle of dark schedule, a 
standard diet that is eating and drinking ad libitum. 
The food consumed comes from Charoen Pokhpand. 
Try animals kept at 25 ± 10°C, 60% relative humidity. 
Mice were preserved during the study period; weight 
was weighed before and after the trial. 
 
Procedures 
Male mice (Mus musculus), DDW strain, 
healthy, weight: 20-30 grams, divided into 4 groups: 1. 
Normal mice as control (-); 2. Mice with aspirin but not 
given intervention (positive control); 3. Mice with oral 
honey for 12 days; and 4. Admission was performed 
on the mice from the first day of the study, for 12 days 
at doses according to the Conversion Dosage Table 
1. 
Table 1: Table Dosing Calculation Calculations (Laurence & 
Bacharach, 1964) orally 
 Mice 20 
gram 
Mouse 
200 gr 
Guinea 
Pig 
400 gr 
Rabbit 1,5 
kg 
Cat 
2 kg 
Monkey 4 
kg 
Dog 
12 kg 
Human 
70 kg 
Mice 
20 gr 
1.0 7.0 12.25 27.8 29.7 64.1 124.2 387.9 
Mouse 200 
gr 
0.14 1.0 1.74 3.9 4.2 9.2 17.8 56.0 
Guinea Pig  
400 gr 
0.08 0.57 1.0 2.25 2.4 5.2 10.2 31.5 
Rabbit 
1,5 kg 
0.04 0.25 0.44 1.0 1.08 2.4 4.5 14.2 
Cat  
2 kg 
0.03 0.23 0.41 0.92 1.0 2.2 4.1 13.0 
Monkey  
4 kg 
0.016 0.11 0.19 0.42 0.45 1.0 1.9 6.1 
Dog  
12 kg 
0.008 0.06 0.1 0.22 0.24 0.52 1.0 3.1 
Human 70 
kg 
0.0026 0.018 0.031 0.07 0.076 0.16 0.32 1.0 
 
Conversion Dosage Calculation: 1. Aspirin: 80 
mg x 0.0026 x 1000: 20 = 10.40 mg / kg BW and 2. 
Honey: 75 mg x 0.0026 x 1000: 20 = 9.75 mg / kg BW; 
After 12 days of intervention, all mice have 
been tested for measuring bleeding time by using 
Duke-Tail bleeding method as follows: 1. The area 
under investigation (tail of mice) has been cleaned 
with cotton alcohol; 2. First, the tail of the mice is cut 
(made wound) at 1 mm diameter using a scalpel and 
let the blood out freely, when the blood starts 
stopwatch is run; and 3. Exhausted blood is sucked 
with filter paper every 30 seconds until the blood stops 
flowing (do not let filter paper touch the wound), the 
stopwatch is stopped when the blood cannot be 
sucked again using filter paper, and the time is 
recorded. 
 
Data Collection 
Data collected in this study were primary data 
obtained from the measurement of bleeding time in 
mice tail after 12 days of intervention.  
 
Data Analysis 
The data obtained have been analysed using 
a computer program. The data have been tested for 
normality by using the Shapiro-Wilk test because of 
the small number of samples. Followed by a 
homogeneity test using the Levene test. The Kruskal-
Wallis non-parametric statistical test is performed 
because the data distribution is normal but the data 
variant is not the same (not homogeneous), followed 
by post hoc analysis using the Mann Whitney test. A 
difference is significant when p < 0.05. 
 
 
Results  
 
Description of Research Location 
This research was conducted in 
Pharmacology Laboratory of Department of 
Pharmacology and Therapeutics Faculty of Medicine, 
University of Sumatera Utara. The location is located 
on Jalan Dr T. Mansur, No. 5, Medan, North 
Sumatera. 
 
Description of Research Sample 
In this study used as many as 32 male mice 
(Mus musculus), Double Ditsch Webster strains age: 
± 3 months (adult), healthy, weight 20-30 grams as a 
sample, which is divided into 4 groups each 
amounting to 8 mice, the control group (placebo), the 
aspirin group and the honey group. 
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Results of Data Analysis 
The antiplatelet effect in mice counted from 
the time of bleeding was analysed using a computer 
program. From the research obtained data as follows: 
Table 2: Bleeding Time Taken for Mice (sec) 
Group  N Mean SD Median Minimum Maximum 
Control 
(Placebo) 
Aspirin 
Honey 
 
8 
 
8 
8 
 
102.88 
 
369.38 
304.63 
 
15.93 
 
120.97 
141.29 
 
101.50 
 
402.00 
380.50 
326.50 
74.00 
 
201.00 
248.00 
129.00 
125.00 
 
507.00 
536.00 
462.00 
 
Data in Table 2 and Figure 1 showed the 
meantime of bleeding at the highest mouse tail was in 
group of mice with aspirin (mean = 369.38 sec) then 
followed by group of mice with honey (mean = 304.63 
seconds), and the lowest was the control group 
(placebo) with a mean value of 102.88 seconds. 
 
Figure 1: Mean Time Bleeding of Mice (sec) 
 
 
Test Data Normality 
Data on bleeding time in each group were 
tested for normality by using the Shapiro-Wilk test. 
The results show that the data is normally distributed 
(p > 0.05), presented in Table 3. 
Table 3: Normality Test Result of Bleeding Time 
Group  N p Explanation 
Control 
(Placebo)  
Aspirin  
Honey  
8 
 
8 
8 
0.847 
 
0.188 
0.133 
Normal 
 
Normal 
Normal 
 
 
Data Homogeneity Test 
Data on bleeding time on mouse tail were 
tested homogeneity by Levene's test. The results 
show a non-homogeneous data variant (p < 0.05), 
presented in Table 4. 
Table 4: Homogeneous Test of Time Bleeding between Groups 
Levene Statistic  df1 df2 Sig. Explanation 
9,760  3 28 0.0001 Not Homogeneous 
 
 
Comparability Test 
The comparability test aims to compare the 
meantime of bleeding in the placebo, aspirin and 
honey groups. Based on the result of the normality 
and homogeneity test, the data in this research are 
normally distributed but do not have the same variant 
(not homogeneous). The comparative analysis used is 
a non-parametric test that is Kruskal-Wallis. Non-
parametric Kruskal-Wallis statistical tests showed 
significant differences in at least two treatment groups 
(p = 0.0001), thus followed by a post hoc analysis with 
Mann Whitney test. 
 
Advanced Test (Post Hoc Test) 
The follow-up test aims to see which groups 
have significant differences. In this study, the follow-
up test used was the Mann Whitney test. The results 
of the test analysis are presented in Table 5. 
Table 5: Data Analysis with Mann Whitney Test 
Group  Control (Placebo) Aspirin Honey 
Control (Placebo)  - 0.001* 0.001* 
Aspirin  0.001* - 0.172 
Honey  0.001* 0.172 - 
  
Data in Table 5 showed that there was a 
significant difference between aspirin and honey 
group to the control group (placebo), i.e., p = 0.001. 
There was no significant difference between aspirin 
group to honey (p = 0.172). 
 
 
Discussion 
 
This study is a true experimental design study 
to prove the effect of antiplatelet on honey and to 
know the comparison of effectiveness between aspirin 
with honey as antiplatelet based on the measurement 
of duration of bleeding in mice tail. The time of 
bleeding is the time to start bleeding on the tail of the 
mice that are cut until the blood stops. The presence 
of antiplatelet effect indicated by honey is 
characterised by the longer time of bleeding after the 
treatment of wound on the tail of mice. 
The average bleeding time in the treatment 
group given honey was longer than the control group 
(placebo) and almost close to the average time of 
positive control group bleeding (aspirin). This is so 
because of flavonoids. One of the contents of honey 
has an antiplatelet activity that can be associated with 
the increased production of prostacyclin by endothelial 
cells. The prostacyclin inhibits the aggregation 
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process through cAMP synthesis which will inhibit the 
expression of GPIIb / IIIa platelet receptors [17]. 
Inhibition of the aggregation process leads to an 
average time of bleeding in the tail of the mouse with 
prolonged honey and propolis. From the statistical 
test, there were significant differences in bleeding time 
in the control group (placebo) against the treatment 
group given honey. In the treatment group treated with 
honey showed no significant difference to the positive 
control group (aspirin). This proves that honey has 
antiplatelet effects in mice as do aspirin. 
The mechanism of inhibition of platelet 
aggregation by honey depends on several factors. A 
study has shown that exposure to hydrogen peroxide 
(one of honey content) can lead to platelet activity 
inhibition of platelet aggregation [18]. Also, honey may 
affect platelet function by inhibiting LDL oxidation that 
indirectly inhibits platelet aggregation [19]. This is 
because research has shown that activated platelets 
after aggregation will produce some cytokines that 
activate phagocytes resulting in increased production 
of oxygen free radicals that will eventually lead to the 
oxidation of LDL [18]. The active component of 
propolis CAPE has been shown to have an 
antiplatelet effect based on the following mechanism 
by increasing the formation of cGMP which will 
activate the cyclic phosphorylation of GMP-dependent 
VASP Ser157 and then inhibit the activity of PKC 
(protein kinase C). In the end, there is inhibition of 
phosphorylation of P47 and triggers the inhibition of 
platelet aggregation [20]. 
From the results of this study, it turns out the 
average time of bleeding in the tail of mice with the 
provision of honey longer or closer to the positive 
control group (aspirin). It can be considered as an 
alternative antiplatelet therapy or as a supplement in 
the prevention of heart disease and blood vessels. 
Therefore, further research needs to be done on 
humans for more effective results as well as doing this 
research using a large sample. 
In conclusion, based on data analysis 
obtained in this study, the conclusions are: 1) this 
study proves that honey can provide an antiplatelet 
effect in mice with the occurrence of lengthening of 
bleeding time on the tail and 2) the mean bleeding 
time in mice tail (304.63 sec) was close to the 
meantime of bleeding with aspirin (369.38 sec) so that 
honey could be considered as a supplement in 
treating heart disease and blood vessels. 
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